To include your compound in the COVID-19 Resource Center, submit it here.

Arbaclofen placarbil: Completed Phase III enrollment

XenoPort disclosed in its 4Q12 earnings that it completed enrollment in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE